VANCOUVER, BC , Aug. 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, released its second...
Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression
/CNW/ - Filament Health Corp. (OTC:FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the...
UCL will study PEX010, the company's botanical psilocybin drug candidate, in trials investigating human perception, cognition, and therapeutic optimization
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that...
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications
/CNW/ - Filament Health Corp. (OTC:FLHLF) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical–stage natural psychedelic drug development company, today announced that...
/CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that...